

# Ondansetron

Catalog No: tcsc2393



## Available Sizes

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

99614-02-5

**Formula:**

$C_{18}H_{19}N_3O$

**Pathway:**

Neuronal Signaling;GPCR/G Protein

**Target:**

5-HT Receptor;5-HT Receptor

**Purity / Grade:**

>98%

**Solubility:**

H2O :

**Alternative Names:**

GR 38032;SN 307

**Observed Molecular Weight:**

293.36

## Product Description

Ondansetron (GR38032) is a serotonin 5-HT<sub>3</sub> receptor antagonist used mainly as an antiemetic (to treat nausea and vomiting), often following chemotherapy.


IC<sub>50</sub> Value:

Target: 5-HT<sub>3</sub> Receptor

in vitro: 5-HT evoked transient inward currents ( $EC_{50} = 3.4 \mu\text{M}$ ; Hill coefficient = 1.8) that were blocked by the 5-HT<sub>3</sub> receptor antagonist ondansetron ( $IC_{50} = 103 \text{ pM}$ ) [1]. The 5-HT<sub>3A</sub> receptor antagonist ondansetron (0.3 nM) reversibly inhibited the 5-HT (30  $\mu\text{M}$ ) signal by 70% and at 3 nM it abolished the response [2].

in vivo: Acute ondansetron administration at the lowest dose (0.1 mg/kg, IP) tested had no effect, while other doses (0.33 and 1 mg/kg, IP) produced improvements in auditory gating [3]. Different doses of ondansetron were injected intraperitoneally (i.p.) at fixed times during the day to determine both the sublethal (TD<sub>50</sub>) and lethal (LD<sub>50</sub>) doses, which were, respectively,  $3.7 \pm 0.6 \text{ mg/kg}$  and  $4.6 \pm 0.5 \text{ mg/kg}$  [4]. Ondansetron (0.25-1.0 mg/kg, subcutaneously) given before the challenge dose of ethanol (2.4 g/kg, intraperitoneally) injection, significantly and dose dependently attenuated the expression of sensitization. In addition, ondansetron (1.0 mg/kg, subcutaneously) given before ethanol injection on days 1, 4, 7, and 10 significantly blocked the development (days 1, 4, 7, and 10), and expression (day 15) of sensitization to the locomotor stimulant effect of ethanol injection [5].

Toxicity: Ondansetron may be safe in lower doses used to prevent nausea and vomiting in radiation treatment or postoperatively. However, as there is a report that a lower dose of ondansetron prolonged the QT interval in healthy volunteers, this needs to be clarified by the FDA [6].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!